Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Arnica Montana, Calcium Sulfide, Hypericum Perforatum, Lycopodium Clavatum Spore, Thiosinaminum, Mercurius Solubilis, Salicylic Acid, Silicon Dioxide, Allylthiourea
Brand Name
Ring Relief Pm Nighttime Formula
Generic Name
Arnica Montana, Calcium Sulfide, Hypericum Perforatum, Lycopodium Clavatum Spore, Thiosinaminum, Mercurius Solubilis, Salicylic Acid, Silicon Dioxide, Allylthiourea
Active Ingredient
AllylthioureaCategory
Vitamin C [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 6 [hp_X]/mL | LIQUID | AURICULAR (OTIC) | 17312-175 |
Detailed information about Ring Relief Pm Nighttime Formula
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Ring Relief Pm Nighttime Formula, you must consult a qualified healthcare professional.
Allylthiourea, historically known as Thiosinamine, is a thiourea derivative used primarily in specialized clinical contexts for its fibrolytic properties. It is often categorized within complex allergenic extracts and historical therapeutic preparations.
Dosage for Allylthiourea varies significantly based on the condition being treated and the specific formulation used.
Allylthiourea is not recommended for pediatric use. There is insufficient clinical data to establish a safe and effective dose for children or adolescents. Because of its potential impact on thyroid function and the developing endocrine system, its use in patients under 18 years of age should be avoided unless specifically directed by a specialist in a controlled clinical setting.
Since Allylthiourea is primarily excreted by the kidneys, patients with a Creatinine Clearance (CrCl) below 50 mL/min require significant dose reductions. In cases of severe renal failure (CrCl < 15 mL/min), the drug is generally contraindicated due to the risk of accumulation and systemic toxicity.
Patients with hepatic impairment (Child-Pugh Class B or C) should use Allylthiourea with extreme caution. The liver's reduced capacity to metabolize the allyl and thiourea moieties can lead to elevated plasma levels and increased risk of hepatotoxicity.
Geriatric patients should start at the lowest end of the dosing range. Providers must account for the natural decline in renal and hepatic function associated with aging, as well as the increased likelihood of concomitant medications that may interact with Allylthiourea.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this increases the risk of side effects.
Symptoms of Allylthiourea overdose may include severe nausea, vomiting, epigastric pain, headache, and signs of hypothyroidism (fatigue, cold intolerance). In severe cases, it may lead to leukopenia (low white blood cell count) or nephrotoxicity.
Emergency Measures: In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on gastric lavage (if caught early) and monitoring of thyroid and renal function.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or discontinue use without medical guidance.
Patients using Allylthiourea, especially in topical forms, frequently report localized skin reactions. These may include:
> Warning: Stop taking Allylthiourea and call your doctor immediately if you experience any of these.
Prolonged use of Allylthiourea may lead to the development of a goiter (enlarged thyroid gland) due to its inhibitory effect on thyroid peroxidase. Chronic exposure may also result in cumulative renal strain. Patients on long-term therapy should undergo periodic blood work to monitor thyroid-stimulating hormone (TSH) levels and complete blood counts (CBC).
No FDA black box warnings are currently issued for Allylthiourea, as it is not a widely used primary systemic therapeutic. However, healthcare providers treat the compound with the same caution as other thiourea-class drugs (like propylthiouracil), which do carry warnings regarding severe liver injury and agranulocytosis.
Report any unusual symptoms to your healthcare provider. Monitoring for skin changes and systemic wellness is essential during the course of treatment.
Allylthiourea is a potent chemical compound that must be used strictly under medical supervision. Because it can affect multiple organ systems—specifically the thyroid and the hematopoietic (blood-forming) system—it is not suitable for self-administration. Patients must be screened for pre-existing thyroid disorders and blood dyscrasias before beginning treatment.
No FDA black box warnings for Allylthiourea. However, its chemical relatives in the thiourea class are known for potential bone marrow suppression.
If you are prescribed Allylthiourea for more than 14 days, your doctor may require the following tests:
Allylthiourea may cause dizziness or headaches in some patients. Do not drive, operate heavy machinery, or engage in hazardous activities until you know how this medication affects you.
Alcohol should be avoided while using Allylthiourea. Alcohol can exacerbate the gastrointestinal side effects and increase the metabolic load on the liver, potentially heightening the risk of hepatotoxicity.
Do not stop using Allylthiourea abruptly if you have been using it for an extended period. While it does not have a traditional "withdrawal syndrome," stopping treatment suddenly may lead to a rebound in the inflammatory processes of the scar tissue. Your doctor will provide a tapering schedule if necessary.
> Important: Discuss all your medical conditions with your healthcare provider before starting Allylthiourea, especially if you have a history of thyroid disease or anemia.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is essential to prevent dangerous interactions.
Allylthiourea must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients who are allergic to Isothiocyanates (found in mustard, horseradish, and wasabi) or Sulfa drugs may exhibit cross-sensitivity to Allylthiourea. If you have experienced a rash or breathing difficulties after consuming hot mustard or taking sulfonamide antibiotics, inform your doctor before using Allylthiourea.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Allylthiourea. Ensure you disclose all past allergic reactions.
Allylthiourea is Contraindicated during pregnancy. It is classified as a potential teratogen. The thiourea moiety easily crosses the placental barrier and can inhibit the development of the fetal thyroid gland, leading to congenital hypothyroidism and potential neurodevelopmental delays. If pregnancy occurs while using this medication, it must be discontinued immediately, and a specialist should be consulted.
It is unknown whether Allylthiourea is excreted in human breast milk. However, due to its low molecular weight and sulfur content, passage into milk is likely. Because of the risk of suppressing the infant's thyroid function or causing skin rashes, breastfeeding is not recommended during treatment. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients have not been established. The potential for endocrine disruption makes Allylthiourea a high-risk choice for children. Its use is generally restricted to adult populations unless no other alternatives exist for severe, disfiguring scarring, and even then, only under strict specialist supervision.
Clinical studies have not included sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, because elderly patients are more likely to have decreased renal and hepatic function, dosage selection should be cautious. There is also an increased risk of drug-drug interactions in this population due to polypharmacy.
In patients with moderate renal impairment (GFR 30-59 mL/min), the dose should be reduced by 50%. In patients with severe impairment (GFR < 30 mL/min), the drug should be avoided. Accumulation of thiourea metabolites can lead to systemic toxicity, including uremic-like symptoms and intensified thyroid suppression.
No specific guidelines exist for Child-Pugh scoring, but patients with visible jaundice or elevated transaminases (>3x the upper limit of normal) should not use systemic Allylthiourea. Topical use should be monitored for signs of systemic absorption.
> Important: Special populations require individualized medical assessment. Always consult a specialist for guidance in these cases.
Allylthiourea exerts its primary effect through fibrolysis. It targets the stabilized collagen matrix in pathological scars. Chemically, the allyl group and the thiourea sulfur atom interact with the intermolecular hydrogen bonds of collagen. This interaction increases the hydration of the scar tissue, making it more susceptible to endogenous collagenase enzymes.
Additionally, Allylthiourea acts as a competitive inhibitor of thyroid peroxidase. By binding to the heme group of the enzyme, it prevents the oxidation of iodide to iodine, thereby blocking the synthesis of thyroxine (T4) and triiodothyronine (T3). This systemic effect is the primary source of its side effect profile.
The onset of the fibrolytic effect is slow, typically requiring 4 to 8 weeks of consistent application to observe visible softening of scar tissue. The duration of effect depends on the maturity of the scar; newer scars (less than 6 months old) respond more rapidly than older, calcified fibrous tissue. There is no evidence of pharmacological tolerance, but the risk of systemic toxicity increases with the duration of use.
| Parameter | Value |
|---|---|
| Bioavailability | 45-60% (Oral) |
| Protein Binding | ~35% |
| Half-life | 4-6 hours |
| Tmax | 1.5 - 2 hours |
| Metabolism | Hepatic (CYP2B6, CYP2E1) |
| Excretion | Renal (75%), Fecal (10%) |
Allylthiourea is a Thiourea Derivative. It is therapeutically categorized as a fibrolytic agent and a chemical allergen. It shares structural similarities with anti-thyroid drugs like thiourea and methylthiouracil, and it is often found in complex allergenic extracts categorized under EPCs such as Vitamin C [EPC] or CNS Stimulants [EPC] in specific multi-ingredient clinical databases.
Common questions about Ring Relief Pm Nighttime Formula
Allylthiourea, also known as Thiosinamine, is primarily used for its ability to soften and reduce scar tissue, such as keloids and hypertrophic scars. It works by breaking down the dense collagen fibers that make up these scars, improving skin flexibility and appearance. Historically, it was also used to treat internal strictures and certain types of deafness caused by fibrous adhesions in the ear. In modern clinical settings, it is sometimes found in diagnostic allergenic extracts used to identify specific chemical sensitivities. Because it is a potent compound, it is only used in specialized cases under medical supervision.
The most common side effects of Allylthiourea include localized skin irritation, such as redness, itching, or a mild burning sensation at the application site. When taken systemically, patients often report a garlicky taste in the mouth, nausea, and occasional headaches. Some individuals may experience 'Thiosinamine fever,' which is a transient immune response characterized by chills and a rise in body temperature. Because it affects the thyroid, symptoms of low thyroid function like fatigue or weight gain can also occur with prolonged use. Most minor side effects resolve once the medication is discontinued, but any persistent symptoms should be reported to a doctor.
It is strongly advised to avoid alcohol while using Allylthiourea. Alcohol can increase the metabolic strain on the liver, which is the primary organ responsible for processing this drug. Furthermore, alcohol may worsen common side effects such as dizziness, headache, and gastrointestinal upset. There is also a risk that alcohol could interact with the drug's effect on blood clotting or thyroid function, leading to unpredictable clinical outcomes. For your safety, refrain from alcohol consumption throughout the duration of your treatment and consult your healthcare provider for specific guidance.
No, Allylthiourea is not considered safe for use during pregnancy and is generally contraindicated. It has the potential to cross the placenta and interfere with the development of the fetal thyroid gland, which is crucial for normal growth and brain development. Exposure during pregnancy could lead to congenital hypothyroidism or other developmental issues in the newborn. Women of childbearing age should use effective contraception while on this medication. If you suspect you are pregnant, stop using the drug immediately and contact your obstetrician or healthcare provider.
Allylthiourea is not a fast-acting medication; its effects on fibrous tissue are gradual and require consistent use. Most patients begin to see a visible softening or flattening of scar tissue after 4 to 8 weeks of regular application. For older or more extensive scars, it may take several months of therapy to achieve the desired results. It is important to follow the prescribed schedule and not increase the frequency of use in an attempt to speed up the process. Your healthcare provider will likely schedule follow-up appointments to monitor your progress and check for any systemic side effects.
While Allylthiourea does not cause a traditional physical dependence, you should not stop taking it suddenly without consulting your doctor, especially if you are using it for a systemic condition. Abrupt discontinuation can sometimes lead to a 'rebound' effect where the inflammatory or fibrotic process in the scar tissue reactivates. If you have been on a long-term course, your doctor may recommend a tapering schedule to safely reduce the dose. Always seek medical advice before making changes to your medication regimen to ensure your condition remains stable. For topical use on small scars, sudden discontinuation is generally less risky but still best discussed with a professional.
If you miss a dose of Allylthiourea, you should apply or take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed one and continue with your regular routine. You should never apply extra cream or take a double dose to make up for the one you missed, as this can increase the risk of localized skin reactions or systemic toxicity. Keeping a consistent schedule is key to the effectiveness of the treatment. If you find yourself frequently forgetting doses, consider using a pill organizer or setting a daily reminder on your phone.
Weight gain is a potential side effect of Allylthiourea, primarily because the drug can suppress thyroid function. As a thiourea derivative, it acts as an antithyroid agent, which can slow down your metabolism and lead to gradual weight increase, lethargy, and cold intolerance. This effect is more common with oral or injectable forms than with topical creams, but systemic absorption can still occur through the skin. If you notice significant, unexplained weight gain while using this medication, your doctor may need to check your TSH (Thyroid Stimulating Hormone) levels. Managing this side effect usually involves adjusting the dose or discontinuing the drug under medical supervision.
Allylthiourea has several significant drug interactions that require careful management. It should not be taken with other anti-thyroid drugs or radioactive iodine, as this can severely damage the thyroid gland. It may also interact with blood thinners like warfarin, increasing the risk of bleeding, and with lithium, which further suppresses thyroid function. Because it is metabolized by the liver, other drugs that affect liver enzymes (like St. John's Wort or certain antibiotics) can change how Allylthiourea works in your body. Always provide your healthcare provider with a full list of all prescription drugs, over-the-counter medicines, and herbal supplements you are currently taking.
Allylthiourea is generally not sold as a standard 'brand-name' or 'generic' prescription drug in the same way as common antibiotics or blood pressure medications. Instead, it is often available as a chemical component for compounding or as part of specialized allergenic extracts. In some regions, it may be found in homeopathic preparations under the name 'Thiosinaminum.' Because it is a niche product, its availability can vary significantly by country and pharmacy. You will likely need to obtain it through a specialist, such as a dermatologist or an allergist, who can order it from a specialized compounding pharmacy.
Other drugs with the same active ingredient (Allylthiourea)